Drug Trial Radar · NCT05714254
Multiple Dose Study of Safety and Pharmacokinetics of MEDI0618 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jan 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Dec 12, 2022
Primary completion
Dec 12, 2023
Study completion Dec 12, 2023
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Feb 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single centre, randomised, double-blind, placebo-controlled, multiple ascending dose study of MEDI0618 in healthy male and female volunteers. Subjects will receive MEDI0618 or placebo administered by intravenous infusion or subcutaneous injection. Safety, tolerability and pharmacokinetics of multiple ascending doses of MEDI0618 will be assessed.
Conditions
- Chronic Pain
Interventions
MEDI0618Drug
Four doses of 100 mg IV, 200 mg IV or 200 mg SC MEDI0618 administered once every two weeks.
PlaceboDrug
Four doses of IV placebo or SC placebo administered once every two weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: From Screening, Day 1 to Day 113
- Incidence of abnormal vital signsTime frame: From Screening, Day 1 to Day 113
- Incidence of abnormal laboratory parametersTime frame: Day -1, Day 15, Day 29, Day 43, Day 57, Day 71, Day 99, Day 113
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.